Patrys Successfully Establishes PAT-DX1 Stable Cell Line

Melbourne, Australia; 10 February 2021: Patrys Limited (ASX: PAB, “Patrys” or the Company), a therapeutic antibody development company, is pleased to announce it has selected an optimised stable cell line for its lead asset PAT-DX1. This important step allows the company to establish large- scale production of PAT-DX1 deoxymab for final preclinical studies, first-in-man studies, and partnering act